Does Rallies show Form 4 insider transactions for CUE?

Yes. Rallies tracks CUE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CUE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.

CUE (Cue Biopharma, Inc.) Stock Analysis - Insider Trades

Cue Biopharma, Inc. (CUE) is a publicly traded Healthcare sector company. As of May 21, 2026, CUE trades at $20.03 with a market cap of $86.50M and a P/E ratio of -16.45. CUE moved -1.53% today. Year to date, CUE is +77.99%; over the trailing twelve months it is +1.70%. Its 52-week range spans $4.97 to $59.67. Rallies surfaces CUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CUE stock inside the company?

Recent CUE insider activity includes Sarraf Pasha bought 4.23K, Sarraf Pasha bought 77.15K, Sarraf Pasha bought 86.95K, Sarraf Pasha bought 78.12K, and Sarraf Pasha bought 77.42K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CUE Key Metrics

Key financial metrics for CUE
Metric	Value
Price	$20.03
Market Cap	$86.50M
P/E Ratio	-16.45
EPS	$-1.21
Dividend Yield	0.00%
52-Week High	$59.67
52-Week Low	$4.97
Volume	387
Avg Volume	0
Revenue (TTM)	$32.73M
Net Income	$-19.52M
Gross Margin	0.00%

Recent CUE Insider Trades

Sarraf Pasha bought 4.23K (~$1.31K) on Dec 30, 2025.
Sarraf Pasha bought 77.15K (~$23.17K) on Dec 30, 2025.
Sarraf Pasha bought 86.95K (~$27.60K) on Dec 30, 2025.
Sarraf Pasha bought 78.12K (~$24.33K) on Dec 30, 2025.
Sarraf Pasha bought 77.42K (~$23.35K) on Dec 30, 2025.

Latest CUE News

Cue Biopharma Raises $30M, Earns $7.5M Milestone, Licenses CUE-221 and Preps INDs — May 14, 2026
Cue Biopharma Names Shao-Lee Lin CEO, Plans Phase 1 CUE-401 and Phase 2 Launch — Apr 30, 2026
1-for-30 Reverse Split to Cut Shares to 3.3M and Secure Nasdaq Listing — Apr 22, 2026
Cue Biopharma Earns $7.5M Preclinical Milestone from Boehringer Ingelheim — Apr 8, 2026
Cue Biopharma Appoints Lucinda Warren Interim CEO to Drive CUE-401 Clinic Entry — Mar 27, 2026

CUE Analyst Consensus

CUE analyst coverage data. Average price target: $0.00.

Common questions about CUE

Who is trading CUE stock inside the company?: Recent CUE insider activity includes Sarraf Pasha bought 4.23K, Sarraf Pasha bought 77.15K, Sarraf Pasha bought 86.95K, Sarraf Pasha bought 78.12K, and Sarraf Pasha bought 77.42K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CUE?: Yes. Rallies tracks CUE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CUE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.